ActiveMSers Forums  

Go Back   ActiveMSers Forums > Forums > Dave's SCT Journey

Thread Tools Display Modes
Prev Previous Post   Next Post Next
Old 07-15-2019, 02:56 PM
ActiveMSers's Avatar
ActiveMSers ActiveMSers is online now
Dave @ ActiveMSers
Join Date: Jun 2008
Location: Albuquerque, NM
Posts: 3,919
Default STUDY: Sustained remission in MS after hematopoietic stem cell transplantation

After 10 years, a 50/50 shot at full remission sounds pretty darn impressive. An important caveat: They all had aggressive forms of relapsing remitting MS, as you can see from an earlier paper they published (immediately below). -D

During the last 15 years, high-dose chemotherapy with autologous hematopoietic stem cell transplantation (HSCT) has globally been performed for severe multiple sclerosis (MS). Most patients have been in progressive phase with long disease duration. As a rule, treatment effect has been minor or moderate. Since 2004, we have performed HSCT in nine young patients with "malignant" relapsing-remitting MS. Criteria for treatment were short duration of disease; very frequent, severe relapses; recent improvement periods indicating potential for recovery after strong immunosuppression. Median age at treatment was 27 (range 9-34) years, MS duration 26 (4-100) months, and annualized relapse rate 10 (4-12). Median Disability Status Scale (extended disability status scale, EDSS) at HSCT was 7.0 (3.5-8.0). Median follow-up time April 2008 is 29 (23-47) months. Median EDSS improvement is 3.5 (1.0-7.0), clearly surpassing most previous reports. One patient relapsed mildly with rapid recovery 7 months after HSCT. All patients are otherwise stable, median EDSS being 2.0 (0-6.0). Before HSCT, 61 relapses occurred in 82 patient months; during follow-up, one relapse in 289 patient months. This small series of patients with "malignant" relapsing-remitting MS suggests HSCT to be an effective treatment option for this relatively rare disease course. It further suggests that future criteria for HSCT in MS should be close to the present ones.
Sustained remission in multiple sclerosis after hematopoietic stem cell transplantation

Andreas Tolf Jan Fagius Kristina Carlson Torbjörn Åkerfeldt Tobias Granberg Elna‐Marie Larsson Joachim Burman

First published: 12 July 2019


To determine if treatment with autologous hematopoietic stem cell transplantation can induce sustained complete remission in patients with multiple sclerosis (MS).

Material and Methods
Case series of patients with relapsing‐remitting MS (n=10) treated at a single center between 2004 and 2007 and followed up for 10 years. The patients were treated with a BEAM/ATG conditioning regimen (n=9) or a cyclophosphamide/ATG conditioning regimen (n=1) followed by infusion of unmanipulated autologous hematopoietic stem cells. The primary endpoint was sustained complete remission. Sustained complete remission was defined as ‘no evidence of disease activity‐4', sustained for a period of at least 5 years without any ongoing disease‐modifying treatment. Furthermore, MS was considered as ‘resolved' if intrathecal IgG production and cerebrospinal fluid neurofilament light levels were normalized as well.

Five out of 10 patients were in sustained complete remission at the end of the study. In 3 of them, MS was resolved.

Our data demonstrate that sustained complete remission after autologous hematopoietic stem cell transplantation for MS is possible.
Dave Bexfield
Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

All times are GMT -4. The time now is 06:54 PM.

Powered by vBulletin® Version 3.7.0
Copyright ©2000 - 2020, Jelsoft Enterprises Ltd.